NEW YORK, Jan 4 (Reuters) - A U.S. federal judge has denied motions to certify classes of users of osteoporosis drug Fosamax who wanted Merck & Co to set up a program to monitor them for an ailment ...

NEW YORK — Lawyers for Fosamax users who believe their jaws were damaged by the osteoporosis drug on Friday asked a federal judge to order Merck & Co. to provide a dental monitoring program for the ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...

Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Alendronate, a drug commonly used to treat osteoporosis, ...

Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found. This finding ...

Compared with alendronate, teriparatide was associated with significantly greater pain reduction and better quality of life among postmenopausal women with osteoporosis. Teriparatide has a favorable ...